Table 15.15 Immunosuppression Use for Maintenance by Regimen Two Years Following Transplantation, 1998 to 2005 Recipients with Heart-Lung Transplants

	Transplant Year							
	1998	1999	2000	2001	2002	2003	2004	2005
Transplants	47	51	48	27	33	29	40	35
Functioning Graft at 2 Years PostTx	20	22	26	18	18	12	29	23
With Maintenance Use Recorded at 2 Years PostTx	20	22	24	16	18	12	28	22
Tac	0.0%	0.0%	4.2%	0.0%	0.0%	0.0%	0.0%	0.0%
Tac + MMF/MPA	0.0%	0.0%	4.2%	6.3%	0.0%	8.3%	0.0%	4.5%
+ OtherAntimet	0.0%	0.0%	4.2%	0.0%	0.0%	0.0%	0.0%	0.0%
Tac + Siro/Evero	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	4.5%
CyA + Steroids	5.0%	9.1%	8.3%	0.0%	0.0%	0.0%	0.0%	0.0%
Tac + Steroids	0.0%	0.0%	4.2%	25.0%	11.1%	0.0%	7.1%	13.6%
CyA + MMF/MPA + Steroids	25.0%	9.1%	16.7%	6.3%	16.7%	8.3%	10.7%	4.5%
Tac + MMF/MPA + Steroids	40.0%	31.8%	16.7%	37.5%	16.7%	41.7%	39.3%	40.9%
+ OtherAntimet + Steroids	0.0%	0.0%	0.0%	0.0%	5.6%	0.0%	3.6%	0.0%
CyA + OtherAntimet + Steroids	20.0%	22.7%	8.3%	0.0%	11.1%	16.7%	7.1%	9.1%
Tac + OtherAntimet + Steroids	10.0%	13.6%	20.8%	12.5%	16.7%	25.0%	21.4%	13.6%
+ Siro/Evero + Steroids	0.0%	0.0%	0.0%	0.0%	5.6%	0.0%	0.0%	0.0%
Tac + Siro/Evero + Steroids	0.0%	9.1%	4.2%	12.5%	16.7%	0.0%	7.1%	4.5%
Other Regimen	0.0%	4.5%	8.3%	0.0%	0.0%	0.0%	3.6%	4.5%

Source: OPTN/SRTR Data as of May 1, 2008.

Percentages are calculated based on the total number of patients with maintenance use at two years following transplantation. They sum to 100 percent for each column. Transplants prior to year 1998 are not reported due to insufficient reporting of immunosuppressive drug use.

MMF: Mycophenolate Mofetil; MPA: Mycophenolate Sodium; Siro: Sirolimus; Evero: Everolimus; OtherAntimet: Antimetabolites excluding MMF and MPA. "Other Regimen" includes drug combinations that are different from the listed regimens and drugs from the text field entering.

^{---:} No Calcineurin Inhibitor Use; CyA: Cyclosporine; Tac: Tacrolimus.